PDS Biotechnology Co. (NASDAQ:PDSB) Given Consensus Recommendation of “Buy” by Analysts

PDS Biotechnology Co. (NASDAQ:PDSBGet Rating) has been given a consensus rating of “Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $21.20.

Separately, StockNews.com upgraded shares of PDS Biotechnology to a “sell” rating in a research report on Saturday, April 9th.

NASDAQ:PDSB opened at $5.16 on Monday. The firm’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $7.99. PDS Biotechnology has a one year low of $4.10 and a one year high of $17.85.

PDS Biotechnology (NASDAQ:PDSBGet Rating) last posted its earnings results on Thursday, March 31st. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same quarter last year, the company earned ($0.16) EPS. On average, analysts expect that PDS Biotechnology will post -0.98 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the company. Voloridge Investment Management LLC increased its stake in shares of PDS Biotechnology by 279.2% in the 3rd quarter. Voloridge Investment Management LLC now owns 49,191 shares of the company’s stock valued at $733,000 after acquiring an additional 36,219 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $632,000. Cubist Systematic Strategies LLC increased its stake in shares of PDS Biotechnology by 187.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 71,618 shares of the company’s stock valued at $1,067,000 after acquiring an additional 46,665 shares in the last quarter. Jump Financial LLC bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $393,000. Finally, Valeo Financial Advisors LLC increased its stake in shares of PDS Biotechnology by 35.7% in the 4th quarter. Valeo Financial Advisors LLC now owns 21,570 shares of the company’s stock valued at $175,000 after acquiring an additional 5,670 shares in the last quarter. Institutional investors own 23.91% of the company’s stock.

PDS Biotechnology Company Profile (Get Rating)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

Featured Stories

Analyst Recommendations for PDS Biotechnology (NASDAQ:PDSB)

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.